{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:33:18Z","timestamp":1792801998657,"version":"4.5.0"},"reference-count":52,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T00:00:00Z","timestamp":1518739200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Tuberculosis Vaccine Initiative","id":[{"id":"https:\/\/ror.org\/01hb96w20","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>The Bacille Calmette Guerin (BCG) vaccine can provide decades of protection against tuberculosis (TB) disease, and although imperfect, BCG is proof that vaccine mediated protection against TB is a possibility. A new TB vaccine is, therefore, an inevitability; the question is how long will it take us to get there? We have made substantial progress in the development of vaccine platforms, in the identification of antigens and of immune correlates of risk of TB disease. We have also standardized animal models to enable head-to-head comparison and selection of candidate TB vaccines for further development.\u00a0 To extend our understanding of the safety and immunogenicity of TB vaccines we have performed experimental medicine studies to explore route of administration and have begun to develop controlled human infection models. Driven by a desire to reduce the length and cost of human efficacy trials we have applied novel approaches to later stage clinical development, exploring alternative clinical endpoints to prevention of disease outcomes. Here, global leaders in TB vaccine development discuss the progress made and the challenges that remain. What emerges is that, despite scientific progress, few vaccine candidates have entered clinical trials in the last 5 years and few vaccines in clinical trials have progressed to efficacy trials. Crucially, we have undervalued the knowledge gained from our \u201cfailed\u201d trials and fostered a culture of risk aversion that has limited new funding for clinical TB vaccine development. The unintended consequence of this abundance of caution is lack of diversity of new TB vaccine candidates and stagnation of the clinical pipeline. We have a variety of new vaccine platform technologies, mycobacterial antigens and animal and human models. \u00a0However, we will not encourage progression of vaccine candidates into clinical trials unless we evaluate and embrace risk in pursuit of vaccine development.<\/ns4:p>","DOI":"10.12688\/f1000research.13588.1","type":"journal-article","created":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T05:55:06Z","timestamp":1518760506000},"page":"199","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":107,"title":["Progress and challenges in TB vaccine development"],"prefix":"10.12688","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1984-5121","authenticated-orcid":false,"given":"Gerald","family":"Voss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo","family":"Casimiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Neyrolles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan H.E.","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"McShane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hatherill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0435-1006","authenticated-orcid":false,"given":"Helen A","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2018,2,16]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12916-016-0685-4","article-title":"The potential impact of BCG vaccine supply shortages on global paediatric tuberculosis mortality.","volume":"14","author":"R Harris","year":"2016","journal-title":"BMC Med."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"15520-15525","DOI":"10.1073\/pnas.1404386111","article-title":"Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries.","volume":"111","author":"G Knight","year":"2014","journal-title":"Proc Natl Acad Sci U S A."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"17-43","DOI":"10.1016\/0041-3879(76)90015-5","article-title":"Impact of BCG vaccination programmes in children and young adults on the tuberculosis problem.","volume":"57","author":"K Styblo","year":"1976","journal-title":"Tubercle."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"1566-1573","DOI":"10.5588\/ijtld.12.0569","article-title":"A rational vaccine pipeline for tuberculosis.","volume":"16","author":"M Brennan","year":"2012","journal-title":"Int J Tuberc Lung Dis."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"1-54","DOI":"10.3310\/hta21390","article-title":"Observational study to estimate the changes in the effectiveness of bacillus Calmette-Gu\u00e9rin (BCG) vaccination with time since vaccination for preventing tuberculosis in the UK.","volume":"21","author":"P Mangtani","year":"2017","journal-title":"Health Technol Assess."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"408-409","DOI":"10.1016\/S1473-3099(16)00134-1","article-title":"BCG vaccination: a long-lasting protection against tuberculosis?--Authors' reply.","volume":"16","author":"P Nguipdop-Djomo","year":"2016","journal-title":"Lancet Infect Dis."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"784-791","DOI":"10.1093\/cid\/cir951","article-title":"Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis.","volume":"54","author":"J Andrews","year":"2012","journal-title":"Clin Infect Dis."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"20130437","DOI":"10.1098\/rstb.2013.0437","article-title":"The ongoing challenge of latent tuberculosis.","volume":"369","author":"H Esmail","year":"2014","journal-title":"Philos Trans R Soc Lond B Biol Sci."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"52-56","DOI":"10.1016\/j.coi.2017.06.010","article-title":"CD8+ T cell programming by cytomegalovirus vectors: applications in prophylactic and therapeutic vaccination.","volume":"47","author":"K Fr\u00fch","year":"2017","journal-title":"Curr Opin Immunol."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"802-813","DOI":"10.1038\/mi.2016.91","article-title":"MR1-restricted mucosal-associated invariant T (MAIT) cells respond to mycobacterial vaccination and infection in nonhuman primates.","volume":"10","author":"J Greene","year":"2017","journal-title":"Mucosal Immunol."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"1077-1078","DOI":"10.1038\/cr.2017.53","article-title":"An mRNA-based vaccine strategy against Zika.","volume":"27","author":"G Wong","year":"2017","journal-title":"Cell Res."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"831-839","DOI":"10.1093\/infdis\/jiv503","article-title":"Pulmonary but Not Subcutaneous Delivery of BCG Vaccine Confers Protection to Tuberculosis-Susceptible Mice by an Interleukin 17-Dependent Mechanism.","volume":"213","author":"N Aguilo","year":"2016","journal-title":"J Infect Dis."},{"key":"ref-13","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01686-16","article-title":"Mucosal BCG Vaccination Induces Protective Lung-Resident Memory T Cell Populations against Tuberculosis.","volume":"7","author":"C Perdomo","year":"2016","journal-title":"MBio."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"174-190","DOI":"10.1016\/j.tube.2016.09.004","article-title":"Alternative BCG delivery strategies improve protection against Mycobacterium tuberculosis in non-human primates: Protection associated with mycobacterial antigen-specific CD4 effector memory T-cell populations.","volume":"101","author":"S Sharpe","year":"2016","journal-title":"Tuberculosis (Edinb)."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"96-108","DOI":"10.1016\/j.chom.2015.06.001","article-title":"Absolute Proteome Composition and Dynamics during Dormancy and Resuscitation of Mycobacterium tuberculosis.","volume":"18","author":"O Schubert","year":"2015","journal-title":"Cell Host Microbe."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"1659-1671","DOI":"10.4049\/jimmunol.1201593","article-title":"An unbiased genome-wide Mycobacterium tuberculosis gene expression approach to discover antigens targeted by human T cells expressed during pulmonary infection.","volume":"190","author":"S Commandeur","year":"2013","journal-title":"J Immunol."},{"key":"ref-17","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-017-0008-6","article-title":"Comprehensive definition of human immunodominant CD8 antigens in tuberculosis.","volume":"2","author":"D Lewinsohn","year":"2017","journal-title":"NPJ Vaccines."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"189-200","DOI":"10.1016\/j.jinf.2015.09.040","article-title":"IFN-\u03b3 and IgA against non-methylated heparin-binding hemagglutinin as markers of protective immunity and latent tuberculosis: Results of a longitudinal study from an endemic setting.","volume":"72","author":"M Belay","year":"2016","journal-title":"J Infect."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1038\/s41598-017-04894-0","article-title":"HLA-E Presents Glycopeptides from the Mycobacterium tuberculosis Protein MPT32 to Human CD8+ T cells.","volume":"7","author":"M Harriff","year":"2017","journal-title":"Sci Rep."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"19570","DOI":"10.1038\/srep19570","article-title":"Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens.","volume":"6","author":"N Knudsen","year":"2016","journal-title":"Sci Rep."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"2312-2322","DOI":"10.1016\/S0140-6736(15)01316-1","article-title":"A blood RNA signature for tuberculosis disease risk: a prospective cohort study.","volume":"387","author":"D Zak","year":"2016","journal-title":"Lancet."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"11290","DOI":"10.1038\/ncomms11290","article-title":"T-cell activation is an immune correlate of risk in BCG vaccinated infants.","volume":"7","author":"H Fletcher","year":"2016","journal-title":"Nat Commun."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"57-63","DOI":"10.1038\/ni.3048","article-title":"The balance between protective and pathogenic immune responses in the TB-infected lung.","volume":"16","author":"I Orme","year":"2015","journal-title":"Nat Immunol."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"167-181","DOI":"10.1111\/imr.12276","article-title":"B cells and antibodies in the defense against Mycobacterium tuberculosis infection.","volume":"264","author":"J Achkar","year":"2015","journal-title":"Immunol Rev."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"e1005687","DOI":"10.1371\/journal.ppat.1005687","article-title":"Patients with Tuberculosis Have a Dysfunctional Circulating B-Cell Compartment, Which Normalizes following Successful Treatment.","volume":"12","author":"S Joosten","year":"2016","journal-title":"PLoS Pathog."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"e1006250","DOI":"10.1371\/journal.ppat.1006250","article-title":"Enhanced control of Mycobacterium tuberculosis extrapulmonary dissemination in mice by an arabinomannan-protein conjugate vaccine.","volume":"13","author":"R Prados-Rosales","year":"2017","journal-title":"PLoS Pathog."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"17537-17542","DOI":"10.1073\/pnas.1202870109","article-title":"Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes.","volume":"109","author":"J Kleinnijenhuis","year":"2012","journal-title":"Proc Natl Acad Sci U S A."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"105-110","DOI":"10.1016\/j.tube.2013.11.003","article-title":"A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data.","volume":"94","author":"H McShane","year":"2014","journal-title":"Tuberculosis (Edinb)."},{"key":"ref-29","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.TBTB2-0004-2015","article-title":"Animal Models of Tuberculosis: An Overview.","volume":"4","author":"A Williams","year":"2016","journal-title":"Microbiol Spectr."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"268-273","DOI":"10.1016\/j.ijid.2017.01.030","article-title":"Experimental animal modelling for TB vaccine development.","volume":"56","author":"P Cardona","year":"2017","journal-title":"Int J Infect Dis."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"845-853","DOI":"10.1080\/14760584.2017.1341316","article-title":"Accelerating tuberculosis vaccine trials with diagnostic and prognostic biomarkers.","volume":"16","author":"S Kaufmann","year":"2017","journal-title":"Exp Rev Vacc."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"276fs278","DOI":"10.1126\/scitranslmed.aaa4730","article-title":"Tuberculosis vaccines: time for a global strategy.","volume":"7","author":"S Kaufmann","year":"2015","journal-title":"Sci Transl Med."},{"key":"ref-33","doi-asserted-by":"publisher","DOI":"10.1101\/222646","article-title":"Cytomegalovirus infection is a risk factor for TB disease in Infants.","author":"J Muller","year":"2017","journal-title":"bioRxiv."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"953-962","DOI":"10.1016\/S2213-2600(15)00435-X","article-title":"Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial.","volume":"3","author":"F Spertini","year":"2015","journal-title":"Lancet Respir Med."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"e0141687","DOI":"10.1371\/journal.pone.0141687","article-title":"A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults.","volume":"10","author":"S Sheehan","year":"2015","journal-title":"PloS One."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"939-946","DOI":"10.1016\/S1473-3099(14)70845-X","article-title":"Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.","volume":"14","author":"I Satti","year":"2014","journal-title":"Lancet Infect Dis."},{"key":"ref-37","doi-asserted-by":"publisher","first-page":"57-64","DOI":"10.1038\/nri2902","article-title":"Experimental human challenge infections can accelerate clinical malaria vaccine development.","volume":"11","author":"R Sauerwein","year":"2011","journal-title":"Nat Rev Immunol."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"1259-1268","DOI":"10.1093\/infdis\/jit647","article-title":"Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate tuberculosis vaccine, MVA85A, alone and in combination.","volume":"209","author":"S Harris","year":"2014","journal-title":"J Infect Dis."},{"key":"ref-39","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00312-17","article-title":"Digitally Barcoding Mycobacterium tuberculosis Reveals In Vivo Infection Dynamics in the Macaque Model of Tuberculosis.","volume":"8","author":"C Martin","year":"2017","journal-title":"MBio."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"650-671","DOI":"10.1128\/MMBR.00021-14","article-title":"Tuberculosis vaccines and prevention of infection.","volume":"78","author":"T Hawn","year":"2014","journal-title":"Microbiol Mol Biol Rev."},{"key":"ref-41","doi-asserted-by":"publisher","first-page":"352-357","DOI":"10.1016\/j.tube.2015.02.036","article-title":"Innovative clinical trial designs to rationalize TB vaccine development.","volume":"95","author":"R Ellis","year":"2015","journal-title":"Tuberculosis (Edinb)."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"1021-1028","DOI":"10.1016\/S0140-6736(13)60177-4","article-title":"Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial.","volume":"381","author":"M Tameris","year":"2013","journal-title":"Lancet."},{"key":"ref-43","doi-asserted-by":"publisher","first-page":"584-591","DOI":"10.1164\/rccm.201409-1704OC","article-title":"The dynamics of QuantiFERON-TB gold in-tube conversion and reversion in a cohort of South African adolescents.","volume":"191","author":"J Andrews","year":"2015","journal-title":"Am J Respir Crit Care Med."},{"key":"ref-44","doi-asserted-by":"publisher","first-page":"e17984","DOI":"10.1371\/journal.pone.0017984","article-title":"The tuberculin skin test versus QuantiFERON TB Gold\u00ae in predicting tuberculosis disease in an adolescent cohort study in South Africa.","volume":"6","author":"H Mahomed","year":"2011","journal-title":"PLoS One."},{"key":"ref-45","first-page":"310-316","article-title":"Comparison of mantoux skin test with three generations of a whole blood IFN-gamma assay for tuberculosis infection.","volume":"10","author":"H Mahomed","year":"2006","journal-title":"Int J Tuberc Lung Dis."},{"key":"ref-46","doi-asserted-by":"publisher","first-page":"470-480","DOI":"10.1093\/cid\/cit790","article-title":"Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials.","volume":"58","author":"P Mangtani","year":"2014","journal-title":"Clin Infect Dis."},{"key":"ref-47","doi-asserted-by":"publisher","first-page":"143-149","DOI":"10.1016\/j.tube.2013.01.003","article-title":"Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG.","volume":"93","author":"M Tameris","year":"2013","journal-title":"Tuberculosis (Edinb)."},{"key":"ref-48","doi-asserted-by":"publisher","first-page":"493-501","DOI":"10.1093\/cid\/cir823","article-title":"Consensus statement on diagnostic end points for infant tuberculosis vaccine trials.","volume":"54","author":"M Hatherill","year":"2012","journal-title":"Clin Infect Dis."},{"key":"ref-49","doi-asserted-by":"publisher","first-page":"778-783","DOI":"10.5588\/ijtld.16.0709","article-title":"Impact of isoniazid preventive therapy on the evaluation of long-term effectiveness of infant MVA85A vaccination.","volume":"21","author":"E Bunyasi","year":"2017","journal-title":"Int J Tuberc Lung Dis."},{"key":"ref-50","doi-asserted-by":"publisher","first-page":"1157-62","DOI":"10.1097\/INF.0000000000000847","article-title":"The Role of Clinical Symptoms in the Diagnosis of Intrathoracic Tuberculosis in Young Children.","volume":"34","author":"H Mulenga","year":"2015","journal-title":"Pediatr Infect Dis J."},{"key":"ref-51","doi-asserted-by":"publisher","first-page":"e0141623","DOI":"10.1371\/journal.pone.0141623","article-title":"Evaluation of Xpert\u00ae MTB\/RIF Assay in Induced Sputum and Gastric Lavage Samples from Young Children with Suspected Tuberculosis from the MVA85A TB Vaccine Trial.","volume":"10","author":"E Bunyasi","year":"2015","journal-title":"PLoS One."},{"key":"ref-52","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12916-016-0617-3","article-title":"Human newborn bacille Calmette-Gu\u00e9rin  vaccination and risk of tuberculosis disease: a case-control study.","volume":"14","author":"H Fletcher","year":"2016","journal-title":"BMC Med."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/7-199\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/7-199\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/7-199\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T06:36:07Z","timestamp":1544078167000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/7-199\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,16]]},"references-count":52,"URL":"https:\/\/doi.org\/10.12688\/f1000research.13588.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.14760.r30908","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.14760.r31832","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.14760.r30908","asserted-by":"object"},{"id-type":"doi","id":"10.5256\/f1000research.14760.r31832","asserted-by":"object"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,16]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/7-199\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.14760.r31832, Rhea Coler, \u00a0Infectious Disease Research Institute (IDRI), Seattle, WA, USA, 12 Mar 2018, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/7-199\/v1#referee-response-31832","order":0,"name":"referee-response-31832","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.14760.r30908, Ashley Birkett, PATH\u2019s Malaria Vaccine Initiative (MVI), Seattle, WA, USA, 13 Mar 2018, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/7-199\/v1#referee-response-30908","order":1,"name":"referee-response-30908","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"This work was supported by the Tuberculosis Vaccine Initiative (TBVI). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}